By Dr Ibon Garitaonandia (CellProthera)2023-07-27T11:00:27
Cell-based therapies have the potential to regenerate heart tissue as an alternative to heart transplants. Here, Dr Ibon Garitaonandia, Chief Scientific Officer at CellProthera, shares how CD34+ cells are demonstrating promising results in clinical studies.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-14T12:32:00Z
Sponsored by Thermo Fisher Scientific
2026-04-14T12:29:00Z
Sponsored by JRS Pharma, In association with Vetter Pharma
2026-04-29T14:00:00Z 2026-04-29T15:00:00Z
Sponsored by USP
2026-05-27T13:00:00Z 2026-05-27T14:00:00Z
Sponsored by TA Instruments
2026-05-27T13:00:00 2026-05-27T14:00:00
Sponsored by TA Instruments
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
2025-06-26T08:43:00
Sponsored by Uniphar, By Tom Smith (Uniphar)
2026-03-18T15:00:00
Sponsored by Sartorius
2025-09-19T15:55:00
Sponsored by Sartorius, By Marko Narobe (Sartorius Biosepartions), Michael Gerrero (BridgeBio) and Srivatsan Ramesh (BridgeBio)
2025-09-24T15:24:00
Sponsored by Lonza
Site powered by Webvision Cloud